Take­da to com­mer­cial­ize Im­muno­Gen’s Ela­here in Japan; Val­ne­va shares safe­ty da­ta for its chikun­gun­ya vac­cine

Take­da plans to pay Im­muno­Gen $34 mil­lion as part of a deal to de­vel­op and com­mer­cial­ize Im­muno­Gen’s can­cer treat­ment Ela­here in Japan.

Im­muno­Gen re­tains ex­clu­sive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER